0001213900-21-053524.txt : 20211019
0001213900-21-053524.hdr.sgml : 20211019
20211019164515
ACCESSION NUMBER: 0001213900-21-053524
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211015
FILED AS OF DATE: 20211019
DATE AS OF CHANGE: 20211019
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FEBBO WILLIAM J
CENTRAL INDEX KEY: 0001413987
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38543
FILM NUMBER: 211331618
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 9TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OptimizeRx Corp
CENTRAL INDEX KEY: 0001448431
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 261265381
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 WATER ST., STE. 200
CITY: ROCHESTER
STATE: MI
ZIP: 48307
BUSINESS PHONE: 248-651-6558
MAIL ADDRESS:
STREET 1: 400 WATER ST., STE. 200
CITY: ROCHESTER
STATE: MI
ZIP: 48307
4
1
ownership.xml
X0306
4
2021-10-15
0
0001448431
OptimizeRx Corp
OPRX
0001413987
FEBBO WILLIAM J
400 WATER STREET, SUITE 200
ROCHESTER
MI
48307
1
1
0
0
CHIEF EXECUTIVE OFFICER
Common Stock (pursuant to 10B5-1 plan)
2021-10-15
4
S
0
16666
84.20
D
502709
D
Performance Stock Units
2021-10-15
4
A
0
182398
0
A
2026-10-15
Common Stock
182398
182398
D
These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Each performance stock unit represents a contingent right to receive one share of the OptimizeRx's common stock. The first 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $98.87 or higher for 30 consecutive trading days during the five-year performance period. Another 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $131.82 or higher for 30 consecutive trading days during the five-year performance period. A final 34% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $164.78 or higher for 30 consecutive trading days during the five-year performance period. If earned, the performance stock units will, subject to certain exceptions, vest ratably on the first anniversary of such performance achievement. Any performance stock unit that has not been earned and vested as of the fifth anniversary of the grant date will be forfeited. Vesting of the performance stock units shall accelerate upon a qualifying termination.
/s/ William Febbo
2021-10-19